Prime Highlight
- MedPal AI has introduced the UK’s first integration of a consumer health app with a regulated online pharmacy, using AI to guide users into personalised treatment pathways.
- The system ensures responsible care, directing only eligible users into clinical assessments for weight management, GLP-1 therapies, and other prescription medicines.
Key Facts
- MedPal AI is an AIM-listed company, with shares trading around 6.5p and a market value of £27.78 million.
- The platform matches users to treatment via independent prescribers, who can review cases and issue electronic prescriptions through MedPal Clinic.
Background
MedPal AI has launched the first direct integration in the UK between a consumer health app and a regulated online pharmacy, using artificial intelligence to guide users into personalised treatment pathways.
The AIM-listed digital health company said its app now analyses aggregated user data, including body mass index, to identify people who may benefit from weight management programmes, GLP-1 therapies or other prescription medicines available through its MedPal Clinic platform.
Unlike broad advertising of weight loss drugs, the system only directs users into a clinical assessment journey if they meet clear eligibility rules. MedPal AI said this approach ensures that support is offered responsibly and under proper medical supervision.
The new feature runs through the company’s AI backend, meaning users do not need to update the app. Eligible users receive a prompt to complete an online assessment on MedPal Clinic, where independent prescribers can review cases and issue electronic prescriptions when appropriate.
Chief executive Jason Drummond said the launch shows the strength of the company’s “dual-engine” model. The business combines a consumer wellness app that generates demand with a regulated pharmacy that delivers treatment.
Drummond said the platform does not simply promote supplements or popular medicines but matches users to care based on their health profile. He described the integration as a step toward truly personalised healthcare.
MedPal AI plans to expand the same AI-led targeting system across other pharmacy services, including medicines for men’s and women’s health that fall under UK electronic prescription rules.
The development comes only months after MedPal AI floated on the AIM market in late August. The company’s shares now trade at around 6.5p, giving it a market value of £27.78 million.
Industry watchers say the model could change how digital health firms connect consumer apps with regulated medical services, especially in areas such as weight management and long-term care.
